On Bon Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
On Bon Chan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Christopher McCormack
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
1 shared publication - Jenny S. W. Yun
Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia
1 shared publication - Michelle Sy Goh
Department of Dermatology, Austin Health, Heidelberg, Victoria, Australia
1 shared publication
Latest Publications
- 13 December 2022
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (1) , 131-137
Bullous pemphigoid associated with anti‐programmed cell death protein 1 and anti‐programmed cell death ligand 1 therapy: A case series of 13 patients
We present a case series of 13 patients, the first Australian single‐centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T‐lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.
- 13 December 2022
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (1) , 131-137
Bullous pemphigoid associated with anti‐programmed cell death protein 1 and anti‐programmed cell death ligand 1 therapy: A case series of 13 patients
We present a case series of 13 patients, the first Australian single‐centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T‐lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.